Literature DB >> 16359856

p63: oncogene or tumor suppressor?

Alea A Mills1.   

Abstract

p53, the original member of the family of genes now known to include p63 and p73, was first heralded as an oncogene because of its potent transformation capabilities and its robust expression in human tumors. However, it was later discovered that only mutant p53 was oncogenic, and that wild type p53 functioned as a tumor suppressor. Decades later, p63, the newest member of this gene family, is involved in a similar controversy: is p63 an oncogene or a tumor suppressor? Recent progress on understanding the in vivo role of p63 in cancer has focused primarily on investigating its involvement in the tumor-suppressive mechanism of apoptosis, by analyzing mouse models to assess its tumor-suppressive capabilities, and by assessing its expression in human cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16359856     DOI: 10.1016/j.gde.2005.12.001

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  35 in total

1.  STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Authors:  Yukihiro Otaka; Susumu Rokudai; Kyoichi Kaira; Michiru Fujieda; Ikuko Horikoshi; Reika Iwakawa-Kawabata; Shinji Yoshiyama; Takehiko Yokobori; Yoichi Ohtaki; Kimihiro Shimizu; Tetsunari Oyama; Jun'ichi Tamura; Carol Prives; Masahiko Nishiyama
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

2.  STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis.

Authors:  Susumu Rokudai; Yingchun Li; Yukihiro Otaka; Michiru Fujieda; David M Owens; Angela M Christiano; Masahiko Nishiyama; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

3.  Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation.

Authors:  Yingchun Li; Melissa J Peart; Carol Prives
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

4.  Structures of p63 DNA binding domain in complexes with half-site and with spacer-containing full response elements.

Authors:  Chen Chen; Natalia Gorlatova; Zvi Kelman; Osnat Herzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-04       Impact factor: 11.205

5.  Expression and regulation of the ΔN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings.

Authors:  Yoshitsugu Mitani; Jie Li; Randal S Weber; Scott L Lippman; Elsa R Flores; Carlos Caulin; Adel K El-Naggar
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

6.  Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63.

Authors:  Bridget E Ferguson-Yates; Hongyan Li; Tiffany K Dong; Jennifer L Hsiao; Dennis H Oh
Journal:  Carcinogenesis       Date:  2007-11-04       Impact factor: 4.944

7.  A MicroRNA196a2* and TP63 circuit regulated by estrogen receptor-α and ERK2 that controls breast cancer proliferation and invasiveness properties.

Authors:  Kyuri Kim; Zeynep Madak-Erdogan; Rosa Ventrella; Benita S Katzenellenbogen
Journal:  Horm Cancer       Date:  2012-12-19       Impact factor: 3.869

Review 8.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

9.  ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.

Authors:  Yiping Huang; Tanusree Sen; Jatin Nagpal; Sunil Upadhyay; Barry Trink; Edward Ratovitski; David Sidransky
Journal:  Cell Cycle       Date:  2008-09-15       Impact factor: 4.534

10.  p63 promotes cell survival through fatty acid synthase.

Authors:  Venkata Sabbisetti; Arianna Di Napoli; Apryle Seeley; Angela M Amato; Esther O'Regan; Musie Ghebremichael; Massimo Loda; Sabina Signoretti
Journal:  PLoS One       Date:  2009-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.